Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBITDA Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed EBITDA Margin for 6 consecutive years, with 780.83% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 780.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 1789.35%, a 159331.0% increase, with the full-year FY2025 number at 1789.35%, up 159331.0% from a year prior.
  • EBITDA Margin was 780.83% for Q4 2025 at Relay Therapeutics, up from 10424.82% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 8030500.0% in Q4 2023 to a low of 83011.76% in Q2 2023.
  • A 5-year average of 484816.27% and a median of 11257.73% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -73978297bps in 2021, then skyrocketed 805600751bps in 2023.
  • Relay Therapeutics' EBITDA Margin stood at 12090.65% in 2021, then plummeted by -111bps to 25507.51% in 2022, then surged by 31583bps to 8030500.0% in 2023, then plummeted by -100bps to 822.91% in 2024, then increased by 5bps to 780.83% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EBITDA Margin are 780.83% (Q4 2025), 10424.82% (Q2 2025), and 990.18% (Q1 2025).